IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype.

Li ZhaoTianyi ZhaoXue YangLing CaoRui XuJiyu LiuCong LinYiyun YuDandan XuanXiaoxia ZhuLei LiuYinghui HuaChunhui DengWeiguo WanHejian ZouYu Xue

Published in: Rheumatology (Oxford, England) (2022)

Our study revealed that IL-37 could shape macrophages into a 'silent' non-inflammatory phagocytic fashion. IL-37 may become a potentially valuable treatment option for patients of chronic gout, especially for those with tophi.

Keyphrases

oxidative stress
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
uric acid
drug induced
combination therapy